Caraco Pharmaceutical Laboratories Ltd
CPD
New York Stock Exchange Arca5.25
USD
+0.01
- -
CIK
0000887708
ISIN
US14075T1079
Return %
Stock
S&P500
1Y
- -
18.46
3Y
- -
64.72
5Y
- -
72.79
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 1150 Elijah McCoy Drive Detroit United States of America 48202
- IPO Date
- Mar 1, 1994
- CIK
- 0000887708
- Similar Companies
- Business
- Caraco Pharmaceutical Laboratories Ltd (NYSE Amex: CPD), a subsidiary of Sun Pharmaceutical Industries Ltd, develops, manufactures, licenses, markets and distributes generic prescription and over-the-counter pharmaceuticals; core products encompass a broad portfolio of generic drugs in various strengths across therapeutic categories including cardiovascular, central nervous system, pain management, anti-infectives, gastrointestinal and allergy treatments, sold primarily to wholesalers, distributors, drugstore chains and managed care providers in the United States; founded in 1984 and headquartered in Detroit, Michigan, with additional packaging operations in Farmington Hills, Michigan, and historical manufacturing ties to facilities in India. The company serves the U.S. generic pharmaceuticals market, targeting large-scale buyers with cost-effective alternatives to branded medications. Sun Pharma, which increased its stake to over 75% by 2011 through strategic purchases and ultimately completed a merger in 2012 that delisted Caraco's shares, continues to consolidate operations under its U.S. portfolio; in 2014, Sun Pharma closed Caraco's Detroit manufacturing facility as part of broader U.S. manufacturing rationalization post-Ranbaxy acquisition, transferring production to other sites while ensuring no supply disruptions; recent Sun Pharma activities include workforce adjustments at Caraco sites in 2013 due to FDA import restrictions and ongoing financial reporting for related entities like Caraco Pharmaceuticals Private Limited in India as of March 2025, reflecting persistent operational challenges and integration efforts.